507 related articles for article (PubMed ID: 9087976)
1. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
LeWitt P; Oakes D; Cui L
Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
[TBL] [Abstract][Full Text] [Related]
2. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
Larsen JP; Boas J
Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
[TBL] [Abstract][Full Text] [Related]
3. Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.
Tison F; Yekhlef F; Chrysostome V; Balestre E; Quinn NP; Poewe W; Wenning GK
Mov Disord; 2002 Jul; 17(4):701-9. PubMed ID: 12210859
[TBL] [Abstract][Full Text] [Related]
4. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.
Ann Neurol; 1996 Jan; 39(1):37-45. PubMed ID: 8572664
[TBL] [Abstract][Full Text] [Related]
5. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
[TBL] [Abstract][Full Text] [Related]
6. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group.
Ann Neurol; 1996 Jan; 39(1):29-36. PubMed ID: 8572663
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
8. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
9. Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial.
Siderowf A; McDermott M; Kieburtz K; Blindauer K; Plumb S; Shoulson I;
Mov Disord; 2002 Jul; 17(4):758-63. PubMed ID: 12210871
[TBL] [Abstract][Full Text] [Related]
10. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
11. Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale.
van Hilten JJ; van der Zwan AD; Zwinderman AH; Roos RA
Mov Disord; 1994 Jan; 9(1):84-8. PubMed ID: 8139609
[TBL] [Abstract][Full Text] [Related]
12. Early addition of selegiline to L-Dopa treatment is beneficial for patients with Parkinson disease.
Mizuno Y; Kondo T; Kuno S; Nomoto M; Yanagisawa N
Clin Neuropharmacol; 2010; 33(1):1-4. PubMed ID: 19935410
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
[TBL] [Abstract][Full Text] [Related]
14. Factor structure of the Unified Parkinson's Disease Rating Scale: Motor Examination section.
Stebbins GT; Goetz CG
Mov Disord; 1998 Jul; 13(4):633-6. PubMed ID: 9686766
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy of parkinsonism with deprenyl.
Behari M; Ahuja GK; Singh K; Prasad K
J Assoc Physicians India; 1992 Jun; 40(6):365-7. PubMed ID: 1452557
[TBL] [Abstract][Full Text] [Related]
16. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.
Weintraub D; Moberg PJ; Duda JE; Katz IR; Stern MB
J Am Geriatr Soc; 2004 May; 52(5):784-8. PubMed ID: 15086662
[TBL] [Abstract][Full Text] [Related]
17. A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.
Marras C; Lang AE; Eberly SW; Oakes D; Fahn S; Schwid SR; Hyson C; Shoulson I;
Mov Disord; 2009 Dec; 24(16):2370-8. PubMed ID: 19908310
[TBL] [Abstract][Full Text] [Related]
18. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
Shoulson I
Ann Neurol; 1998 Sep; 44(3 Suppl 1):S160-6. PubMed ID: 9749589
[TBL] [Abstract][Full Text] [Related]
19. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
20. Subthalamic nucleus stimulation applied in the earlier vs. advanced stage of Parkinson's disease - retrospective evaluation of postoperative independence in pursuing daily activities.
Yamada K; Hamasaki T; Kuratsu J
Parkinsonism Relat Disord; 2009 Dec; 15(10):746-51. PubMed ID: 19481492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
